In vivo Antibody Discovery
Precision BioTools antibody development process uses B cell isolation and cloning to discover highly specific antibodies which meet our customers’ needs. Our process is fully customizable including:
Immunization Strategy
Customize every aspect of your immunization plan to meet your project’s unique requirements, including the species, the number of animals, and the option for additional boosts.
Counter Screening
Enhance specificity and reduce off-target binding with counter screening at both polyclonal and monoclonal stages, ensuring high-quality antibodies.
Final Deliverable
Choose the deliverable that fits your needs, whether it’s the purified antibody protein or just the sequence, providing flexibility for downstream applications.
Polymorphism Specific Antibodies
KRAS, a Kirsten ras oncogene homolog from the mammalian ras gene family, encodes a protein that is a member of the small GTPase superfamily. An amino acid substitution at position 12 is responsible for an activating mutation. The transforming protein that results is implicated in various malignancies, including lung, pancreatic and colorectal cancers.
The Epivolve(R) antibody IGT-0084 is able to distinguish between KRAS G12G and KRAS G12D in immunofluorescence and western blot experiments
This EPIVOLVE® IgG is now available for purchase from Aviva Systems Biology!
Virus Neutralizing Antibodies
EPIVOLVE® antibodies have shown exceptional neutralizing capabilities, effectively targeting and neutralizing a broad range of SARS-CoV-2 variants. This includes both the primary strain and the highly transmissible Omicron variant, which has demonstrated significant immune evasion properties. These antibodies offer robust protection by targeting conserved epitopes, ensuring cross-variant efficacy. This makes EPIVOLVE® antibodies a powerful tool for combating the evolving challenges of the COVID-19 pandemic, supporting both therapeutic and diagnostic applications.
Splice Site Specific Antibodies
EPIVOLVE® antibodies are engineered to offer unparalleled specificity, as demonstrated by their ability to distinguish between splice variants of the CENP-A protein in western blot analysis. These antibodies specifically recognize the presence or absence of Exon 3, enabling researchers to differentiate between the deletion and inclusion forms of CENP-A. This precise targeting is critical for studying splice variant dynamics and their implications in cellular processes, disease progression, and therapeutic interventions. EPIVOLVE® antibodies set a new standard for accuracy and reliability in splice site-specific applications.
GPCR Antibodies
EPIVOLVE® antibodies have been validated to specifically bind CCR5-overexpressing cells in flow cytometry, showcasing their exceptional sensitivity and selectivity. CCR5, a critical chemokine receptor involved in immune response and a co-receptor for HIV entry, is a key target in various research and therapeutic applications. The ability of EPIVOLVE® antibodies to distinguish cells with elevated CCR5 expression provides researchers with a powerful tool for studying receptor dynamics, cellular interactions, and disease mechanisms. This specificity ensures accurate analysis and reliable data for advanced immunological studies and therapeutic development.